Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial
- PMID: 27476789
- DOI: 10.1016/S2352-3026(16)30057-6
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial
Abstract
Background: Venous thromboembolism occurs commonly in patients with cancer. Direct oral anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous thromboembolism. We hypothesised that edoxaban, a direct oral inhibitor of activated clotting factor Xa, might be more suitable than conventional anticoagulants in the management of cancer-associated venous thromboembolism. The aim of this study was to assess the efficacy and safety of edoxaban compared with warfarin in a subgroup of patients with cancer enrolled in the Hokusai-VTE trial.
Methods: We did a prespecified subgroup analysis in August, 2013, and a post-hoc analysis of non-inferiority and safety in March, 2016, of the patients with cancer enrolled in the randomised, double-blind, double-dummy, multicentre, Hokusai-VTE trial done between Jan 28, 2010, and Oct 31, 2012. In this study, patients aged at least 18 years with acute symptomatic deep-vein thrombosis or acute symptomatic pulmonary embolism (with or without deep-vein thrombosis) were assigned to receive edoxaban 60 mg once per day (or 30 mg once per day for patients with a creatinine clearance of 30-50 mL/min, bodyweight <60 kg, or who were receiving concomitant treatment with the P-glycoprotein inhibitors quinidine or verapamil) or warfarin (dose adjusted to maintain the international normalised ratio between 2·0 and 3·0) or placebos for either group for at least 3 months up to 12 months. All patients received initial therapy with open-label enoxaparin or unfractionated heparin for at least 5 days. Edoxoban (or placebo) was started after discontinuation of initial heparin; warfarin (or placebo) started concurrently with the study regimen of heparin. In our analysis we examined data for a subgroup of these patients who had a history of cancer or who had been categorised as having active cancer by the study physician at the time of enrolment. Additionally, all patients with a history of cancer were reviewed post hoc and categorised according to the presence or absence of active cancer. The primary efficacy outcome was the proportion of these patients with symptomatic recurrent venous thromboembolism during the 12-month study period, analysed in the modified intention-to-treat population, with an upper limit of the CI for the hazard ratio (HR) of 1·5. The principal safety outcome was the proportion of patients who had clinically relevant bleeding in the population of patients who received at least one dose of the study drug. This study is registered with ClinicalTrials.gov, number NCT00986154.
Findings: Of 771 patients with cancer enrolled in the trial, 378 were assigned to edoxaban and 393 to warfarin. Recurrent venous thromboembolism occurred in 14 (4%) of 378 patients given edoxaban and in 28 (7%) of 393 patients given warfarin (hazard ratio [HR] 0·53, 95% CI 0·28-1·00; p=0·0007). The upper limit of this 95% CI did not exceed the non-inferiority margin of 1·5 that was prespecified for the trial. Clinically relevant bleeding (major or non-major) occurred in 47 (12%) of 378 patients who received edoxaban and in 74 (19%) of 393 patients who received warfarin; HR for clinically relevant bleeding 0·64, 95% CI 0·45-0·92; p=0·017. Major bleeding occurred in ten (3%) of 378 patients with a history of cancer who received edoxaban and in 13 (3%) of 393 who received warfarin (HR 0·80, 95% CI 0·35-1·83).
Interpretation: Edoxaban might be as effective as warfarin for the treatment of patients with cancer with venous thromboembolism, and with less clinically relevant bleeding. Additional clinical trials of edoxaban versus low-molecular-weight heparin for the treatment of venous thromboembolism in patients with cancer are warranted.
Funding: Daiichi Sankyo.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Comment in
-
Direct oral anticoagulants and cancer: no swansong yet for the low-molecular-weight heparins.Lancet Haematol. 2016 Aug;3(8):e357-8. doi: 10.1016/S2352-3026(16)30065-5. Epub 2016 Jul 1. Lancet Haematol. 2016. PMID: 27476784 No abstract available.
Similar articles
-
Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.Lancet Haematol. 2016 Sep;3(9):e437-45. doi: 10.1016/S2352-3026(16)30080-1. Lancet Haematol. 2016. PMID: 27570090 Clinical Trial.
-
Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.Lancet Haematol. 2016 May;3(5):e228-36. doi: 10.1016/S2352-3026(16)00023-5. Epub 2016 Mar 22. Lancet Haematol. 2016. PMID: 27132697 Clinical Trial.
-
Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial.J Thromb Haemost. 2015 Sep;13(9):1606-14. doi: 10.1111/jth.13055. Epub 2015 Aug 27. J Thromb Haemost. 2015. PMID: 26179767 Clinical Trial.
-
Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.Cardiol Rev. 2016 Jul-Aug;24(4):205-10. doi: 10.1097/CRD.0000000000000104. Cardiol Rev. 2016. PMID: 26991962 Review.
-
Edoxaban tosylate.Am J Cardiovasc Drugs. 2011;11(2):129-35. doi: 10.2165/11533660-000000000-00000. Am J Cardiovasc Drugs. 2011. PMID: 21446778 Review.
Cited by
-
Comparing Anticoagulation Strategies for Venous Thromboembolism Associated With Active Cancer: A Systematic Review and Meta-Analysis.JACC CardioOncol. 2024 Jan 9;6(1):99-113. doi: 10.1016/j.jaccao.2023.10.009. eCollection 2024 Feb. JACC CardioOncol. 2024. PMID: 38510285 Free PMC article.
-
Cancer-Associated Venous Thromboembolism: Changes Over the Past 20 Years.JACC CardioOncol. 2023 Dec 19;5(6):773-774. doi: 10.1016/j.jaccao.2023.10.007. eCollection 2023 Dec. JACC CardioOncol. 2023. PMID: 38205015 Free PMC article.
-
Low-Dose Rivaroxaban to Prevent Recurrences of Venous Thromboembolism in Cancer: A Real-Life Experience with a Focus on Female Patients.J Clin Med. 2023 Oct 9;12(19):6427. doi: 10.3390/jcm12196427. J Clin Med. 2023. PMID: 37835070 Free PMC article.
-
Long-term mortality in patients with pulmonary embolism: results in a single-center registry.Res Pract Thromb Haemost. 2023 Jun 14;7(5):100280. doi: 10.1016/j.rpth.2023.100280. eCollection 2023 Jul. Res Pract Thromb Haemost. 2023. PMID: 37601025 Free PMC article.
-
Direct-Acting Oral Anticoagulant Therapy in Cancer Patients-A Review.Cancers (Basel). 2023 May 10;15(10):2697. doi: 10.3390/cancers15102697. Cancers (Basel). 2023. PMID: 37345034 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources